|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leclère B, Molinié F, Trétarre B, Stracci
F, Daubisse-Marliac L and Colonna M; GRELL Working Group: Trends in
incidence of breast cancer among women under 40 in seven European
countries: A GRELL cooperative study. Cancer Epidemiol. 37:544–549.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Curtis C, Shah SP, Chin SF, Turashvili G,
Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et
al METABRIC Group: The genomic and transcriptomic architecture of
2,000 breast tumours reveals novel subgroups. Nature. 486:346–352.
2012.PubMed/NCBI
|
|
4
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stevens KN, Vachon CM and Couch FJ:
Genetic susceptibility to triple-negative breast cancer. Cancer
Res. 73:2025–2030. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cleator S, Heller W and Coombes RC:
Triple-negative breast cancer: Therapeutic options. Lancet Oncol.
8:235–244. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang AC, Jellinek DA and Reddel RR:
Mammalian stanniocalcins and cancer. Endocr Relat Cancer.
10:359–373. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoshiko Y and Aubin JE: Stanniocalcin 1 as
a pleiotropic factor in mammals. Peptides. 25:1663–1669. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yeung BH, Law AY and Wong CK: Evolution
and roles of stanniocalcin. Mol Cell Endocrinol. 349:272–280. 2012.
View Article : Google Scholar
|
|
11
|
Varghese R, Wong CK, Deol H, Wagner GF and
DiMattia GE: Comparative analysis of mammalian stanniocalcin genes.
Endocrinology. 139:4714–4725. 1998.PubMed/NCBI
|
|
12
|
Fujiwara Y, Sugita Y, Nakamori S, Miyamoto
A, Shiozaki K, Nagano H, Sakon M and Monden M: Assessment of
Stanniocalcin-1 mRNA as a molecular marker for micrometastases of
various human cancers. Int J Oncol. 16:799–804. 2000.PubMed/NCBI
|
|
13
|
Joensuu K, Heikkilä P and Andersson LC:
Tumor dormancy: Elevated expression of stanniocalcins in late
relapsing breast cancer. Cancer Lett. 265:76–83. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu G, Yang G, Chang B, Mercado-Uribe I,
Huang M, Zheng J, Bast RC, Lin SH and Liu J: Stanniocalcin 1 and
ovarian tumorigenesis. J Natl Cancer Inst. 102:812–827. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tamura S, Oshima T, Yoshihara K, Kanazawa
A, Yamada T, Inagaki D, Sato T, Yamamoto N, Shiozawa M, Morinaga S,
et al: Clinical significance of STC1 gene expression in patients
with colorectal cancer. Anticancer Res. 31:325–329. 2011.PubMed/NCBI
|
|
16
|
Block GJ, Ohkouchi S, Fung F, Frenkel J,
Gregory C, Pochampally R, DiMattia G, Sullivan DE and Prockop DJ:
Multipotent stromal cells are activated to reduce apoptosis in part
by upregulation and secretion of stanniocalcin-1. Stem Cells.
27:670–681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He LF, Wang TT, Gao QY, Zhao GF, Huang YH,
Yu LK and Hou YY: Stanniocalcin-1 promotes tumor angiogenesis
through up-regulation of VEGF in gastric cancer cells. J Biomed
Sci. 18:392011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Du YZ, Gu XH, Li L and Gao F: The
diagnostic value of circulating stanniocalcin-1 mRNA in non-small
cell lung cancer. J Surg Oncol. 104:836–840. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: New insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Egeblad M and Werb Z: New functions for
the matrix metal-loproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim S, Choi JH, Lim HI, Lee SK, Kim WW,
Cho S, Kim JS, Kim JH, Choe JH, Nam SJ, et al: EGF-induced MMP-9
expression is mediated by the JAK3/ERK pathway, but not by the
JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. Cell
Signal. 21:892–898. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han J, Bae SY, Oh SJ, Lee J, Lee JH, Lee
HC, Lee SK, Kil WH, Kim SW, Nam SJ, et al: Zerumbone suppresses
IL-1β-induced cell migration and invasion by inhibiting IL-8 and
MMP-3 expression in human triple-negative breast cancer cells.
Phytother Res. 28:1654–1660. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Westermarck J, Holmström T, Ahonen M,
Eriksson JE and Kähäri VM: Enhancement of fibroblast collagenase-1
(MMP-1) gene expression by tumor promoter okadaic acid is mediated
by stress-activated protein kinases Jun N-terminal kinase and p38.
Matrix Biol. 17:547–557. 1998. View Article : Google Scholar
|
|
25
|
Juneja J, Cushman I and Casey PJ: G12
signaling through c-Jun NH2-terminal kinase promotes breast cancer
cell invasion. PLoS One. 6:e260852011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bachmeier BE, Albini A, Vené R, Benelli R,
Noonan D, Weigert C, Weiler C, Lichtinghagen R, Jochum M and
Nerlich AG: Cell density-dependent regulation of matrix
metalloproteinase and TIMP expression in differently tumorigenic
breast cancer cell lines. Exp Cell Res. 305:83–98. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang MC, Chen CA, Chen PJ, Chiang YC,
Chen YL, Mao TL, Lin HW, Lin Chiang WH and Cheng WF: Mesothelin
enhances invasion of ovarian cancer by inducing MMP-7 through
MAPK/ERK and JNK pathways. Biochem J. 442:293–302. 2012. View Article : Google Scholar
|
|
28
|
Zhou X, Hua L, Zhang W, Zhu M, Shi Q, Li
F, Zhang L, Song C and Yu R: FRK controls migration and invasion of
human glioma cells by regulating JNK/c-Jun signaling. J Neurooncol.
110:9–19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fang Z, Tian Z, Luo K, Song H and Yi J:
Clinical significance of stanniocalcin expression in tissue and
serum of gastric cancer patients. Chin J Cancer Res. 26:602–610.
2014.PubMed/NCBI
|
|
30
|
Shirakawa M, Fujiwara Y, Sugita Y, Moon
JH, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Mori M and Doki
Y: Assessment of stanniocalcin-1 as a prognostic marker in human
esophageal squamous cell carcinoma. Oncol Rep. 27:940–946.
2012.
|
|
31
|
Peña C, Céspedes MV, Lindh MB, Kiflemariam
S, Mezheyeuski A, Edqvist PH, Hägglöf C, Birgisson H, Bojmar L,
Jirström K, et al: STC1 expression by cancer-associated fibroblasts
drives metastasis of colorectal cancer. Cancer Res. 73:1287–1297.
2013. View Article : Google Scholar
|
|
32
|
Guo F, Li Y, Wang J, Li Y, Li Y and Li G:
Stanniocalcin1 (STC1) inhibits cell proliferation and invasion of
cervical cancer cells. PLoS One. 8:e539892013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim S, Lee J, Jeon M, Nam SJ and Lee JE:
Elevated TGF-β1 and -β2 expression accelerates the epithelial to
mesenchymal transition in triple-negative breast cancer cells.
Cytokine. 75:151–158. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Davis RJ: Signal transduction by the JNK
group of MAP kinases. Cell. 103:239–252. 2000. View Article : Google Scholar : PubMed/NCBI
|
